Virus-like particles, methods of preparation, and immunogenic compositions
US-9045727-B2 · Jun 2, 2015 · US
VLPS containing ligands and methods related thereto
US9683020B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9683020-B2 |
| Application number | US-201214236618-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 31, 2012 |
| Priority date | Aug 1, 2011 |
| Publication date | Jun 20, 2017 |
| Grant date | Jun 20, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.
First claim
Opening claim text (preview).
What we claim: 1. A method of vaccinating a subject comprising administering an antigen wherein the antigen consists of four copies of M2e polypeptide of SEQ ID NO: 1, in combination with a virus-like carrier comprising a flagellin in a membrane-anchored form comprising a polypeptide of SEQ ID NO: 28, wherein the virus-like carrier does not contain the antigen, under conditions such that antibodies to the antigen are produced. 2. The method of claim 1 , wherein the antigen and virus-like carrier are administered intranasally or intramuscularly. 3. An immunogenic composition comprising an antigen wherein the antigen consists of four copies of M2e polypeptide of SEQ ID NO: 1 and a virus like carrier comprising a flagellin in a membrane-anchored form comprising a polypeptide of SEQ ID NO: 28 wherein the virus-like carrier does not contain the antigen.
Assignees
Inventors
Classifications
Virus like particles [VLP] · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
containing a signal sequence · CPC title
Proteins; Peptides · CPC title
characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9683020B2 cover?
- This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.
- Who is the assignee on this patent?
- Compans Richard W, Wang Baozhong, Quan Fu Shi, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).